Suven Life Sciences has obtained four product patents, two each from China and Korea. These correspond to the new chemical entities (NCEs) for the treatment of disorders connected to the brain functions.
The patents would be valid through 2025 and 2027, respectively, said the Hyderabad-based company.
With these patents, Suven has a total of five granted patents from China and seven from Korea. The company is developing therapeutic agents which would be useful in the treatment of diseases like Alzheimer’s, Parkinson, Schizophrenia and attention deficient hyperactivity disorder, a release said.
Mr Venkat Jasti, CEO of Suven, said: “Suven is developing a pipeline of molecules in the central nervous system (CNS) area to meet the demands to treat disorders like the above with an estimated market potential of $30 billion globally.”